Benzinga··Nabaparna BhattacharyaAIM ImmunoTech Surges 73% on Japanese Patent Victory for Cancer Therapy
AIM ImmunoTech ($AIMT) surged 73.66% after securing Japanese patent approval for Ampligen cancer therapy through 2039, strengthening its immuno-oncology portfolio.
AIMintellectual propertyorphan drug designation